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Axonal spheroidsNiemann–Pick disease type C (NPC) is an inherited lysosomal storage disease characterised by accumulation
of cholesterol and glycosphingolipids. NPC patients suffer a progressive neurodegenerative phenotype pre-
senting with motor dysfunction, mental retardation and cognitive decline. To examine the onset and progres-
sion of neuropathological insults in NPC we have systematically examined the CNS of a mouse model of NPC1
(Npc1−/−mice) at different stages of the disease course. This revealed a speciﬁc spatial and temporal pattern
of neuropathology in Npc1−/−mice, highlighting that sensory thalamic pathways are particularly vulnerable
to loss of NPC1 resulting in neurodegeneration in Npc1−/− mice. Examination of markers of astrocytosis and
microglial activation revealed a particularly pronounced reactive gliosis in the thalamus early in the disease,
which subsequently also occurred in interconnected cortical laminae at later ages. Our examination of the
precise staging of events demonstrate that the relationship between glia and neurons varies between brain
regions in Npc1−/− mice, suggesting that the cues causing glial reactivity may differ between brain regions.
In addition, aggregations of pre-synaptic markers are apparent in white matter tracts and the thalamus
and are likely to be formed within axonal spheroids. Our data provide a new perspective, revealing a number
of events that occur prior to and alongside neuron loss and highlighting that these occur in a pathway depen-
dent manner.
© 2011 Elsevier Inc. All rights reserved.Introduction
Niemann–Pick type C (NPC) is one of more than 50 inherited lyso-
somal storage disorders (LSDs), and like many of these disorders, is
characterised by progressive neurological decline (Brady et al.,
1966; Crocker and Farber, 1958). Neurological signs include ataxia,
mental retardation, tremors, vertical supranuclear gaze palsy and de-
mentia (Garver et al., 2007; Vanier, 2010). This disease can present
neonatally, in childhood, adolescence or during adulthood resultingCaudate putamen; GFAP, glial
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rights reserved.in a broad clinical spectrum of disease severity (Imrie et al., 2007;
Tang et al., 2010; Vanier, 2010).
NPC has historically been thought of as a cholesterol storage disor-
der, as cholesterol accumulates in the liver and spleen, and is redis-
tributed in the brain (Garver et al., 2007). However a plethora of
lipids accumulate in NPC disease including neutral glycosphingoli-
pids, gangliosides, sphingomyelin and sphingosine (Vanier, 1999).
In the brain, which is the major site of NPC disease pathology, there
is signiﬁcant accumulation of gangliosides and sphingolipids (Siegel
and Walkley, 1994; Vanier, 1999; Zervas et al., 2001). There is cur-
rently no consensus on what the functional role of the NPC disease
pathway is and which metabolite is the central player in pathogenesis
(Lloyd-Evans and Platt, 2010).
NPC displays an autosomal recessive mode of inheritance, with
approximately 95% of cases caused by mutations in the NPC1 gene
(Carstea et al., 1997; Greer et al., 1998) and the remaining cases caused
by mutations in NPC2 (Krull et al., 1993; Naureckiene et al., 2000). The
NPC2 protein is a soluble cholesterol binding protein (Garver and
Heidenreich, 2002; Krull et al., 1993), and although NPC1 is thought
to contribute to the transport of lipids the precise function of this pro-
tein remains incompletely understood (Lloyd-Evans and Platt, 2010;
Sturley et al., 2004).
1087S.N.R. Pressey et al. / Neurobiology of Disease 45 (2012) 1086–1100Npc1-null mutant mice (Npc1−/−) (Loftus et al., 1997) have proved a
useful tool for examining the impact of Npc1 deﬁciency, recapitulating
many biochemical, pathological, neurological and behavioural features
of human NPC disease. These include cholesterol and glycosphingolipid
storage, loss of Purkinje cells of the cerebellum, axonal swelling, neuronal
vacuoles and progressive motor impairments such as ataxia, tremor and
loss of co-ordination (Baudry et al., 2003; Morris et al., 1982; Pentchev
et al., 1984; Võikar et al., 2002). Following a progressive loss of body
weight these mice die between 10 and 12 weeks of age (Pentchev et al.,
1984).
Despite a thorough knowledge of the genetic basis of NPC disease,
the underlying pathogenesis of this disease remains unclear and has
turned out to be complex. Forming appropriate hypotheses on the
mechanisms of neurodegeneration requires prior knowledge of the
neuropathology that occurs as a result of loss of the NPC1 protein.
Although the entire central nervous system (CNS) lacks the NPC1 gene,
it is becoming apparent that the effects upon the CNS are selective.
While the Purkinje neurons of the cerebellum are known to be particu-
larly vulnerable to neurodegeneration (Higashi et al., 1993; Pentchev
et al., 1984), less is known about the effects of NPC disease on the rest
of the brain. Therefore, to increase our understanding of how Npc1
deﬁciency impacts upon the CNS we have systematically examined
the onset and progression of neuropathological events including
glial activation, atrophy and neuron loss in Npc1−/− mice.
Material and methods
Npc1 deﬁcient mice
A spontaneous mutant mouse model of NPC on a BALB/C background
was used in this study (Npc1−/−) (Pentchev et al., 1984) with wild-type
littermates (+/+) used as controls. Npc1−/− mice were maintained by
heterozygous mating and the genotype of offspring was determined by
polymerase chain reaction, as described previously (te Vruchte et al.,
2004).Micewere bred and housed under standard non-sterile conditions
at the University of Oxford. All animal procedures were conducted using
protocols approved by theUKAnimals (Scientiﬁc Procedures) Act (1986).
Histological analysis
To analyze the onset and progression of CNS pathology in Npc1 de-
ﬁcient mice, the brains of mutant mice and age-matched controls
(n=5) were examined at 3 time points during their life span repre-
senting presymptomatic (3 weeks), early symptomatic (6 weeks)
and late symptomatic (9 weeks).
Npc1−/− and control mice were perfused and tissue processed for
histology according to established protocols (Bible et al., 2004; Kielar
et al., 2007; Pontikis et al., 2004). Brieﬂy, mice were deeply anaesthe-
tised with sodium pentobarbitone (1 g/kg) and transcardially per-
fused with phosphate buffered saline (PBS) (Sigma-Aldrich, Poole,
UK), followed by a freshly made and ﬁltered solution of 4% Parafor-
maldehyde (PFA) in 0.1 M phosphate buffer, pH 7.4. Brains were re-
moved and post-ﬁxed in 4% PFA at 4 °C for 24 h, then bisected along
the midline. Single hemispheres were cryoprotected in 30% sucrose,
0.5% sodium azide in 50 mM tris buffered saline (TBS), pH 7.6 prior
to cutting frozen sections. 40 μm frozen coronal sections through
the rostrocaudal extent of the cortical mantle were collected one
per well in 96 well plates containing a cryoprotective solution (30%
ethylene glycol (Sigma-Aldrich), 15% sucrose, 0.05% sodium azide in
TBS) (Bible et al., 2004). All subsequent histological analyses were
performed blind to genotype.
Nissl staining
To provide direct visualisation of neuronal cytoarchitecture every
sixth section through each brain was slide mounted and Nissl stainedwith cresyl violet (Bible et al., 2004; Kielar et al., 2007). Brieﬂy, slides
were incubated in 0.05% cresyl fast violet (Merck, Darmstadt, DE),
0.05% acetic acid in water for 30mins at 60 °C, rinsed in deionised
water, then differentiated through an ascending series of alcohols be-
fore clearing in xylene and coverslipped with DPX (VWR, Poole, UK)
(Bible et al., 2004; Kielar et al., 2007).
Immunohistochemistry
A standard immunohistochemical protocol was used to examine
the distribution of markers of interest (Bible et al., 2004; Pressey et
al., 2010), using either 3,3′-diaminobenzidine tetrahydrochloride
(DAB) or ﬂuorescent probes for visualisation.
For visualisation with DAB, endogenous peroxidase activity was
quenched in 1% hydrogen peroxidase (VWR) in TBS for 15 min. Sections
were then rinsed in TBS and blocked in 15% normal serum (Vector,
Northampton, UK) in TBS with 0.3% Triton-X (TBS-T, Sigma-Aldrich),
before incubation in the appropriate primary antibody; polyclonal rab-
bit anti-GFAP (DakoCytomation 1:4000, Ely, UK), rat anti-mouse F4/80
(Serotec 1:100, Oxford, UK), rat anti-CD68 (Serotec 1:2000), mouse
anti-synaptophysin (Cambridge Bioscience 1:200, Cambridge, UK),
mouse anti-synaptobrevin (VAMP2) (Synaptic systems 1:2000, Goet-
tingen, Germany), mouse anti-SNAP25 (BD Biosciences 1:1000, Oxford,
UK) in 10% normal serum in TBS-T overnight at 4 °C. Sectionswere next
rinsed in TBS and incubated with the appropriate biotinylated second-
ary antibodies; swine anti-rabbit (DakoCytomation 1:1000), rabbit
anti-rat (Vector 1:200) and goat anti-mouse (Vector 1:1000) for 2 h at
room temperature. Subsequently, sections were rinsed in TBS, followed
by incubation in avidin-biotin-peroxidase complex (Vectastain Elite
ABC kit, Vector, 1:1000) in TBS for 2 h and then rinsed in TBS. To visual-
ise immunoreactivity, sectionswere incubated in 0.05% DAB (Sigma-Al-
drich) containing 0.001% hydrogen peroxide in TBS for up to 25 min,
depending on the antigen and then rinsed in ice-cold TBS. Finally, sec-
tions were mounted on gelatine-chrome-coated Superfrost microscope
slides (VWR), air-dried overnight, cleared in xylene, and coverslipped
with DPX (VWR).
Immunoﬂuorescence staining was used to investigate the poten-
tial co-localization of the pre-synaptic marker synaptophysin with
the GABAergic marker GAD 65/67. Sections were blocked in 15% nor-
mal serum in TBS-T, then probed with the appropriate primary anti-
bodies: mouse anti-synaptophysin (Cambridge Bioscience 1:200),
rabbit anti-GAD 65/67 (Millipore 1:1000, Watford, UK) in 10% normal
serum in TBS-T overnight at 4 °C. After being rinsed in TBS and incu-
bated with the appropriate ﬂuorescent secondary Alexa-ﬂuor anti-
bodies (Molecular Probes 1:1000, Invitrogen, Carlsbad, CA) for 2 h
at room temperature, sections were rinsed in TBS and mounted on
gelatine-chrome-coated microscope slides and coverslipped with
ﬂuoromount-G (Southern Biotech, Birmingham, AL).
Regional volume, cortical thickness and cell number estimation
Stereological estimates were obtained using StereoInvestigator
software (Microbrightﬁeld Inc, Williston, VT), with regions of interest
deﬁned by referring to the neuroanatomical landmarks described in
Hof et al. (2000) and in Paxinos and Franklin (2001). Cavalieri estimates
of regional volume (Kielar et al., 2007; Pressey et al., 2010) were
obtained from the Nissl stained sections described above. A sampling
grid was superimposed over the region of interest and the number of
points covering the relevant area was assessed. The volume in μm3
was estimated from a series of sections through each region of interest.
Sampling grids and series used were as follows: Cortex, 1:12, 250 μm2;
striatum, 1:12, 150 μm2; thalamus, 1:12, 200 μm2; hippocampus, 1:6,
200 μm2; corpus callosum, 1:12, 100 μm2 and internal capsule and cere-
bral peduncle, 1:6, 100 μm2. Analyses were carried out on an Olympus
BX50 microscope (Olympus, Southend-on-Sea, UK) linked to a DAGE-
MTI CCD-100 camera (Dage-MTI, Michigan City, IA).
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sured the thickness of selected cortical sub-divisions; somatosensory
barrelﬁeld cortex (S1BF), primary visual cortex (V1), primary motor
cortex (M1), primary auditory cortex (Au1) and lateral entorhinal
cortex (LEnt). In each region ten perpendicular lines were traced
from the pial surface of the cortex to the white matter of the corpus
callosum and the mean length used as a measure of thickness. This
was calculated in three consecutive sections starting from a deﬁned
rostrocaudal level for each region (Bible et al., 2004; Kielar et al.,
2007).
The optical fractionator probe was used to estimate cell number
(West et al., 1991) in Nissl stained sections of thalamic relay nuclei
and lamina IV and VI of the S1BF (Kielar et al., 2007; Pressey et al.,
2010). Nissl stained cells were counted, using a 100× objective and
counted as neurons if they had a neuronal morphology and a clearly
identiﬁable nucleus. As such, astrocytes and microglia with their
small soma, or cells with indistinct morphology were not counted. A
line was traced around the boundary of the region of interest, a grid
was superimposed and cells were counted within a series of dissector
frames placed according to the sampling grid size. Different grid and
dissector sizes were used in each brain region using a coefﬁcient
of error (CE) value of less than 0.1 to indicate sampling efﬁciency
(Gundersen et al., 1999). For thalamic nuclei, a 1:6 series was sampled
using the following sampling schemes: LGNd grid 125×125 μm,
frame 74×42 μm; VPM, grid 175×175 μm, frame 74×42 μm; VPL,
grid 100×100 μm, frame 74×42 μm. For the S1BF, a 1:12 series was
sampled using the following sampling schemes: lamina IV, grid
150×150 μm, frame 41×26 μm; lamina VI, grid 200×200 μm, frame
60×40 μm.
Western blotting
To determine the levels of synaptic protein expression, western
blots were performed on crude synaptic preparations (Hruska et al.,
1978; Kadota and Kadota, 1973). After cervical dislocation, brains
were bisected along the midline and the left hemisphere was dissect-
ed to produce cortical and subcortical samples. Tissues were collected
into ice cold homogenization buffer containing 4 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), 0.32 M sucrose,
1 mM MgCl2, 0.5 mM CaCl2, pH7.3, containing proteinase inhibitors
(ROCHE, Welwyn Garden City, UK) and homogenized with a Teﬂon
homogenizer at 700 rpm with 15 up and down strokes. Samples
were centrifuged at 1000 g for 10 min at 4 °C, the pellet was resus-
pended in 0.5 ml homogenization buffer and centrifuged again
under the same conditions. Next, the combined supernatant was cen-
trifuged at 13800 g for 15 min at 4 °C and the pellet was resuspended
in 50 μl homogenization buffer (enriched synaptic fraction). The pro-
tein concentration was determined using a bicinchoninic acid protein
kit (Thermo-Fischer Scientiﬁc, Northumberland, UK) and 2 μg from
each sample was subjected to electrophoresis in a precast 10–20%
Tris–HCl Mini-PROTEAN Gel (Bio-Rad, Hemel Hempstead, UK). Gels
were blotted onto PVDF membranes, blocked with Odyssey blocking
buffer (Li-COR Biosciences, Lincoln, NE) 1:1 PBS-Tween-20 (referred
to as blocking buffer) for 1 h at room temperature and then incubated
with the following primary antibodies diluted in blocking buffer at
4 °C overnight: mouse anti-synaptophysin (Cambridge Bioscience
1:1000), mouse anti-synaptobrevin (VAMP2) (Synaptic systems
1:10 000). After washing, membranes were incubated with ﬂuorescent
goat anti mouse IR-Dye 800 secondary antibody (Li-COR Biosciences
1:10 000) for 1 h at room temperature. After washing, immunoreactive
bands were visualised using an Odyssey Infrared Imaging System
(Li-COR Biosciences), at a scan resolution of 169 μm. Membranes were
next stripped of antibodies using Restore-PLUS western blot stripping
buffer (Thermo-Fischer Scientiﬁc) and reprobed for Mouse anti-Actin
(Abcam, Cambridge UK 1:5000) as a loading control. Quantiﬁcation
was performed on single channels with the analysis software provided.Arbitrary ﬂuorescence values were assigned to bands, giving relative
ﬂuorescence intensity between bands on each membrane and values
were normalised to actin. Three mice were used for each brain region.
Statistical analysis
Microsoft Excel (Redmond, WA) was used for data collection and
SPSS (SPSS Inc. Chicago, IL) for statistical analysis. To test for signiﬁ-
cance between genotypes, the Student's t-test or ANOVA test with
post hoc Bonferroni analysis were used as appropriate. All graphs
are plotted as the mean±the standard error of the mean (SEM).
Results
Regionally localised neuropathology in Npc1−/− mice
The severe neurological phenotypes displayed by Npc1−/−mice are
accompanied by marked changes in both neurons and glia (Baudry
et al., 2003; German et al., 2002; Suzuki et al., 2003), but the onset
and progression of these events have not been characterised in detail.
To further understand the time course of neuropathological changes
in Npc1−/− mice we have systematically examined the forebrain of
Npc1−/−mice at different stages of disease progression.
Astrocytosis and microglial activation can be sensitive markers of
ongoing neuronal dysfunction or injury (Raivich et al., 1999). To
explore which regions of the brain suffer injury in Npc1−/− mice,
we used the astrocyte marker GFAP (Eng et al., 2000) and the
microglial marker CD68 (Kunisch et al., 2004), initially to perform
a low power survey of severely affected Npc1−/− mice (9 weeks).
This revealed widespread activation of both astrocytes and microglia
and highlighted the thalamus as a focus of this immune reaction com-
pared to other brain regions (Fig. 1a*). Prominent staining for both
GFAP and CD68 was also present in the deeper laminae VI of primary
sensory cortical regions (Fig. 1a**), the substantia nigra (Fig. 1a+) and
to a lesser extent in the ventral lateral striatum (Fig. 1a X). In compari-
son, activation of both astrocytes and microglia was more diffuse in
the hippocampus ofNpc1−/−mice (Fig. 1a), with no sub-ﬁeld displaying
more activation than any other. At thismagniﬁcation the overall atrophy
of the 9 week-old Npc1−/− brain was also apparent. Using the Cavalieri
stereological probe for regional volume we found that this was a result
of signiﬁcantly reduced volume of the striatum, thalamus and cortex,
with only the hippocampus remaining unaffected in Npc1−/− mice at
9 weeks of age (Fig. 1c). Examination of younger mice revealed that
this atrophy appeared to be a relatively late stage phenotype,with no at-
rophy of these regions evident in 6 week-old mutant mice (Fig. 1b).
Localised thalamic glial activation
Closer examination of GFAP (astrocytes), F4/80 and CD68 (micro-
glia) immunoreactivity in the thalamus revealed that this intense re-
active gliosis was made up of a series of selective effects within
different thalamic nuclei during disease progression. Upregulation
of these glial markers began early in pathogenesis, with localised
patches of astrocytosis and reactive microglia already evident in
3 week-old Npc1−/− mice. This gliosis was evident only in selected
thalamic nuclei, the majority of which relay sensory information
(Table 1, Figs. 2b, 3b–c). With disease progression, this reactive gliosis
spread to encompass increasingly more thalamic nuclei (Table 1). The
sensory nuclei that displayed the earliest reactive gliosis at 3 weeks of
age (ventral posterior nucleus (VPM/VPL; somatosensory), the dorsal
lateral geniculate nucleus (LGNd; visual) and the medial geniculate
(MGN; auditory)), were those that later displayed the most pro-
nounced gliosis in end-stage 9 week old Npc1−/− mice (Figs. 2a,
3a). The progressive nature of this immune response was also evident
through the morphological transformation of microglia. In 3 week-
old Npc1−/− mice F4/80 immunoreactivity revealed ramiﬁed
Fig. 1. Prominent thalamic glial activation and widespread CNS atrophy in Npc1−/− mice. a Immunohistochemical staining for the astrocyte marker glial ﬁbrillary acidic protein
(GFAP) and the microglial marker CD68 revealed reactive glia throughout the CNS of Npc1−/− mice at disease end stage (9 weeks of age). Reactive astrocytes and microglia
displayed a similar spatial distribution with the most intense immunoreactivity for both markers in the thalamus (*). In addition, localised gliosis was evident in lamina VI
of primary somatosensory cortex (**), the ventral lateral striatum (X) and the substantia nigra (+) (Scale bar; 500 μm). b–c Cavalieri estimates of regional volume revealed
signiﬁcant atrophy of the striatum, thalamus and cortex, but not the hippocampus in 9 week–old Npc1−/−mice compared to wild type controls (c). This atrophy was only apparent
at disease end stage, and was not present in 6 week-old Npc1−/−mice (b). (Hipp, Hippocampus; Thal, Thalamus; Error bars show SEM, n=4–5, ** pb0.01; *** pb0.001).
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(Fig. 3b, F4/80 inserts), indicating a low level of activation. However,
by 6 weeks of age, microglia in these nuclei displayed amoeboid mor-
phology with large round cell bodies and short thickened processes
(Fig. 3a–b, inserts), an indication of activated brain macrophage-like
state (Raivich et al., 1999).
Localised cortical pathology
In comparison to the thalamus, the cortex of Npc1−/− mice
displayed a much lower level of reactive gliosis (Fig. 1). However,
similar to the events in the thalamus glial activation was most evident
in sensory cortical regions. The most intense reactive gliosis seen in
the cortex of Npc1−/− mice was a localised band of densely packed
astrocytes and microglia in the most dorsal part of lamina VI of the
somatosenory barrelﬁeld cortex (S1BF) (Figs. 4a, 5a–b). In addition,
comparison of cortical subﬁelds that serve different functions revealed
that reactive astrocytes were more densely packed in the sensory
S1BF and the primary visual cortex (V1), compared to the primary
motor cortex (M1) (Fig. 4a). To examine whether the cortical atrophy
evident in 9 week-old Npc1−/− mice (Fig. 1c) was also selective for
these different subﬁelds we made thickness measurements of cortical
subﬁelds that serve different functions. This revealed selective atrophy
of sensory regions of the cortex, whereas the lateral entorhinal (LEnt)
and M1 were spared (Fig. 4b).
In addition, F4/80 immunoreactivity revealed that microglia were
rarely morphologically transformed into brain macrophages in the cor-
tex, with these cells maintaining long, branched processes, even at dis-
ease end stage (Fig. 5a inserts). However, in addition to these typical
ramiﬁedmicroglia in the cortex ofNpc1−/−mice, there were occasional
microglia withmultiple long, straight branches extendingmuch further
than the usual reach of a single microglial cell (Fig. 5c). These rod-shaped F4/80 and CD68 positive cells were apparent in small clumps
and sparsely distributed in the cortex, and were evident most often in
sensory and ventral cortical regions adjacent to the corpus callosum.
Staged neuron loss in the thalamocortical system
To examine the relationship between glial activation and neuron
loss through the thalamocortical systemwe focussed upon the thalamic
nuclei (VPM, VPL, LGNd) and cortical regions (S1BF), which displayed
the most intense localised glial activation. This approach also enabled
the examination of interconnected regions since the S1BF is the cortical
target region of the VPM/VPL, where lamina IV granule neurons receive
afferent inputs from the VPM/VPL and lamina VI neurons send efferent
feedback projections to the thalamus.
Optical fractionator estimates of neuron number revealed that
neuron loss was already evident in the LGNd and VPM thalamic nuclei
in 3 week-oldmutantmice (Figs. 6a, c). Only subsequently did neuron
loss become signiﬁcant in the VPL at 6 weeks of age (Fig. 6b). In all
three thalamic nuclei there was a signiﬁcant drop in neuron number
inNpc1−/−mice between 3 and 6 weeks of age (pb0.05 ANOVA), sug-
gesting that a substantial insult to neuron survival in these thalamic
nuclei occurs between these ages. In contrast, neuron loss in S1BF
was a later event, with a signiﬁcant difference between Npc1−/−
mice and controls at 6 weeks of age in lamina VI (Fig. 6e), and at
9 weeks of age in lamina IV (Fig. 6d). In both these laminae, the
most signiﬁcant decrease in the number of neurons occurred between
6 and 9 weeks of age (pb0.003, ANOVA), revealing a later onset
neuron loss in the cortex compared to the thalamus of Npc1−/−
mice. Taken together, our data show localised pathological changes
within interconnected thalamocortical pathways, with neuron loss
apparent earlier in disease progression in the thalamus than the
cortex, reﬂecting the pattern of reactive gliosis.
Table 1
Tabular representation of the distribution of localised astrocytosis and microglial
activation in thalamic nuclei in Npc1−/−mice. A scoring of the intensity of immunoreac-
tivity for GFAP (astrocytes), F4/80 and CD68 (microglia) in different thalamic nuclei is
shown at the 3 age points examined. The number of+signs denotes the intensity of
GFAP, F4/80 and CD68+ve staining along a scale as follows: +++++, nucleus full of
densely packed and intensely stained+ve cells; +++, +ve cells covering at least half
the nucleus; blank, no or very few positive cells detected.
Grouping Modality Thalamic nuclei Intensity of gliosis
Early:
3 wks
Mid:
6 wks
End:
9 wks
Sensory Somatosensory Ventral lateral
posterior (VPL)
++ ++
++
++
++
+
Somatosensory Ventral medial
posterior (VPM)
++ ++
++
++
++
+
Somatosensory Posterior thalamic
nuclear group (Po)
+ ++ ++
+
Auditory Medial geniculate
(MGN)
++ ++
+
++
++
Visual Dorsal lateral
geniculate (LGNd)
+ ++
++
++
++
Visual Ventral lateral
geniculate (LGNv)
+ +
Effector Motor Ventral lateral (VL) ++ ++
+
++
+
Limbic Drive, motivation,
emotion
Medial dorsal central
(MDC)
+ ++ ++
Physiological
response to stress
Anteroventral (AV) + +
Visual and Limbic
connections
Lateral dorsal (LP) + ++ ++
Anteromedial
Associative Somatosenory and
visual integration
Lateral posterior (LP) + ++ ++
Olfaction Submedial (Sub) + ++
Medial dorsal lateral,
medial (MDL, MDM)
Reticular Arousal,
rhythmicity
Reticular (Rt) + ++
++
++
++
Intralaminar Arousal, attention Parafasicular (Pf) +
Intralaminar Autonomic drive Paracentral (PC)
Effector Motor Ventromedial (VM)
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In addition to this thalamocortical pathology, the basal ganglia also
displayed localised intense reactive gliosis (Fig. 1a). In the substantia
nigra, a progressive upregulation of glial markers was evident from an
early age, with partially transformed microglia evident in both the pars
compacta and reticularis from 3 weeks of age (Fig. 7a). Subsequently,
GFAP immunoreactivity was also increased in mutant mice at 6 weeks
of age, and was more prominent in the dorsal part of the substantia
nigra reticularis (SNr). This speciﬁcity for the dorsal part of the SNr
wasmirrored by CD68 immunoreactivity, but surprisingly, F4/80 immu-
noreactivity was distributed evenly throughout the SNr (Fig. 7a). Com-
pared to this early onset reactive gliosis, pronounced gliosis in the
globus pallidus was only evident at a late stage in the 9 week-old
Npc1−/−mice (Fig. 2a**).
In the striatum of Npc1−/− mice, staining for either F4/80 or CD68
revealedmanymicrogliawith rod-likemorphology (Fig. 7b). In contrast
to the cortex (where rod-like microglia were sparsely distributed),
multiple clumps of these cells were evident consistently in the
ventral lateral part of the caudate putamen (CPu) of the striatum.
This phenotype was an early event, with many rod-like microglia
evident in 3 week-old Npc1−/− mice. GFAP staining revealed that
astrocytes were also upregulated in this region, but these astrocytes
did not display any unusual morphological features and were
only mildly hypertrophied (data not shown).Early white matter pathology
Our survey of the Npc1−/− forebrain also revealed that white mat-
ter tracts displayed particularly pronounced glial activation. In
3 week-old Npc1−/− mice, many intensely stained astrocytes and
microglia were apparent in the corpus callosum (Fig. 8a), internal
capsule (Fig. 8b) and the cerebral peduncle (data not shown). Distinct
from grey matter structures, in which microglia remained ramiﬁed in
3 week-old Npc1−/− mice, we observed fully transformed amoeboid
microglia in the white matter of 3 week-old Npc1−/−mice (Fig. 8a in-
serts). This gliosis was associated with a consistently reduced volume
of white matter tracts compared to controls at all stages of disease
progression (Figs. 8c–d).Aberrant synaptic protein aggregation
Our ﬁndings of white matter pathology, and existing evidence for
axonal damage in Npc1−/−mice (March et al., 1997; Ong et al., 2001;
Takikita et al., 2004) suggests that sites distal from the cell body may
be pathologically affected in these mice. To further understand any
neurodegenerative process in these structures, we examined a repre-
sentative selection of synaptic markers normally expressed in either
pre- or post- synaptic compartments. While examination of two
post-synaptic markers (Homer-1 and gephyrin) revealed a pattern
of immunoreactivity in Npc1−/− similar to that seen in control mice
(data not shown), large clusters of three pre-synaptic markers
[synaptophysin, synaptobrevin (vesicle associated membrane
protein-2, VAMP2), and soluble synaptosomal-associated protein of
25 kDa (SNAP25)] were evident in both subcortical grey and white
matter in Npc1−/−mice. In control mice, staining for these presynap-
tic markers revealed punctate immunoreactivity within the neuropil,
leaving neuronal soma as pale unstained structures in grey matter re-
gions and very little staining in white matter (Fig. 9). In marked con-
trast, in Npc1−/− mice aggregates of immunoreactivity appeared
most prominently in the internal capsule and spread through the re-
ticular (Rt) and the VPM/VPL thalamic nuclei (Figs. 9a–b). Additional-
ly, in the VPM/VPL of these mutant mice there was a general decrease
in the level of synaptophysin and VAMP2 immunoreactivity in the
neuropil, different to the normal expression of these synaptic markers
(Figs. 9a–b). These large aggregates were already evident in 3 week-
old mice and were most frequently immunoreactive for synaptophy-
sin and VAMP2, with fewer SNAP25 positive clusters (Fig. 9b). In
Npc1−/− mice, aggregates of presynaptic markers were abundant in
many of the regions that displayed reactive gliosis, including the stri-
atum, substantia nigra, white matter tracts (Fig. 9a, x internal cap-
sule) and the thalamus (Fig. 9a, * VPM/VPL). In contrast, only very
occasional aggregates were evident in the cortex and hippocampus.
To determine whether these changes were associated with an
overall increase or decrease in presynaptic marker expression,
enriched synaptic fractions from cortical and subcortical forebrain tis-
sue were run on western blots and probed for synaptophysin and
VAMP2 (Fig. 10). Quantitative immunoﬂuorescence scanning of
these blots revealed no overall difference in the level of these pre-
synaptic markers after normalisation to actin in either the cortex or
subcortical tissue. This suggests a redistribution rather than up- or
down-regulation of these presynaptic markers.
The large size, morphology and distribution of the aggregates of
presynaptic markers are characteristic of the axonal spheroids that
develop in neurons in many neuropathic lysosomal storage disorders,
including NPC (March et al., 1997; Walkley et al., 1991; Zervas et al.,
2001). To examine this phenotype in more detail, we used dual chan-
nel immunoﬂuorescence staining of GAD65/67 (as a marker of
GABAergic neurons) and synaptophysin. This revealed axonal spher-
oids immunoreactive for both GAD65/67 and synaptophysin in the
VPM/VPL (Fig. 9c yellow arrows). However, not all GABAergic
Fig. 2. Pronounced astrocytosis in the thalamus of Npc1−/−mice. Immunohistochemical staining for glial ﬁbrillary acidic protein (GFAP) revealed striking upregulation of this mark-
er in the thalamus of Npc1−/− mice compared to control mice (+/+). a GFAP immunoreactivity was most intense in the reticular thalamic nucleus (Rt), the ventral posterior nu-
cleus (VPM/VPL), the dorsal lateral geniculate nucleus (LGNd) and themedial geniculate nucleus (MGN) in 9 week-oldNpc1−/−mice (The intense GFAP immunoreactivity adjacent to the
LGNd is amore posterior portion of theVPM/VPL). b Reactive astrocytosiswas already evident in theVPM/VPL and LGNd of 3 week-oldNpc1−/−mice and progressed in intensitywith age.
Basal ganglia nuclei indicated by; ** Globus pallidus, * Substantia nigra (Scale bar=500 μm, except in B LGNd pictures where scale bar=250 μm).
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of synaptophysin were evident in non-GABAergic cells (red arrows).
These data suggest that the neurodegenerative process in Npc1−/−
mice also involves sites distal from the cell body, with pronounced
aggregation of synaptic markers displayed in the regions with the
most pronounced reactive gliosis.
Discussion
In this study we have examined progressive hallmarks of neuropa-
thology in Npc1−/− mice with the aim of understanding the selective
impact of loss of NPC1 upon the CNS. This has revealed that in addi-
tion to motor structures (such as the cerebellum and basal ganglia,
which are characteristic of NPC), marked pathology is also evident
within interconnected sensory pathways. Our survey of glial markers
highlighted that thalamic nuclei relaying sensory information are an
early site of pathological insult, with neuron loss already evident in
the youngest mutant mice examined. In addition to identifying this
regionally localised pathology, we provide evidence to suggest that
neurodegenerative insults are present in the more distal parts of neu-
rons before the cell body is affected in Npc1−/− mice.
Localised pathology within interconnecting sensory pathways
NPC disease primarily results in motor impairment associated
with cerebellar degeneration (Higashi et al., 1993; Sarna et al.,
2003), and neuropathology in related motor structures such as the
basal ganglia (Baudry et al., 2003). Apart from these insults upon
the motor system, neuron loss is also reported in the thalamus, cortex
and selected brain stem nuclei at disease end stage (German et al.,
2001; Luan et al., 2008; Yamada et al., 2001). However, the onlyreport to examine the events preceding this neuron loss outside the
cerebellum was Yamada et al. (2001), who showed evidence of
early neuron loss in the thalamus from 4 weeks of age.
Using unbiased stereological methods, we have conﬁrmed and
extended these original observations (Yamada et al., 2001), revealing
that speciﬁc populations of relay neurons are lost early in disease
progression in the thalamus of Npc1−/−mice (Fig. 6). Furthermore we
have obtained signiﬁcant new data for other neuropathological events
that are most pronounced in the sensory thalamocortical system of
these mice. Indeed, our data indicate that these pathways are an early
pathological target of disease in Npc1−/− mice; we demonstrate that
there is already signiﬁcant neuron loss in multiple thalamic nuclei in
3 week-old Npc1−/− mice (Fig. 6) long before the onset of symptoms
is apparent. Furthermore, by also examining the onset of neuron loss
in the cortex, we have deﬁned the staging of neuropathology within
these interconnected thalamocortical pathways in Npc1−/− mice. We
demonstrate that somatosensory relay neurons are lost ﬁrst in the
VPM thalamic nuclei, followed by the sequential loss of feedback
cortical neurons in lamina VI of the S1BF and ﬁnally loss of lamina IV
granule neurons, which receive input from the VPM/VPL (Fig. 6f).
These new data highlight that sensory thalamic pathways are
particularly vulnerable to loss of NPC1 resulting in neurodegeneration
in Npc1−/−mice.
Prominent reactive gliosis in the thalamocortical system
Neurons are just one component of the brain, relying upon their
close interactions with glia, the support cells of the brain. While each
type of glial cell plays important roles within the healthy CNS, in disease
states they may alter their morphology, cell surface antigen expression
or in the case of microglia, proliferate (Bradl and Lassmann, 2010;
Fig. 3. Profound microglial activation in the thalamus of Npc1−/− mice. Immunohistochemical staining for the microglial markers F4/80 and CD68 revealed upregulation of
these markers in the thalamus of Npc1−/− mice compared to controls. a F4/80 and CD68 immunoreactivity was most striking in the reticular thalamic nucleus (Rt), the
ventral posterior nucleus (VPM/VPL), the dorsal lateral geniculate nucleus (LGNd) and the medial geniculate nucleus (MGN) in 9 week-old Npc1−/− mice. Higher power
pictures reveal the amoeboid morphology of microglia indicating their activated state (The intense F4/80 and CD68 immunoreactivity in the LGNd panel is a more posterior
portion of the VPM/VPL). b–c F4/80 and CD68 immunoreactivity was already evident in 3 week-old Npc1−/− mice in selected thalamic nuclei including VPM/VPL (b) and
LGNd (c). Higher power pictures (b) reveal the morphological transformation of microglia from a more ramiﬁed morphology at 3 weeks of age to amoeboid microglia by
6 weeks of age. (Scale bar: 200 μm in low power images; 20 μm in inserts).
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a number of previous reports demonstrating an upregulated immune
response (Baudry et al., 2003; German et al., 2001; German et al.,
2002; Luan et al., 2008; Suzuki et al., 2003), but this is the ﬁrst detailed
description of glial activation in relation to the neuron loss that subse-
quently occurs. Recent evidence suggests that this glial activation is
not the primary contributor to neuron loss, since neuron-speciﬁc resto-
ration of Npc1 expression in transgenic mice is sufﬁcient to mitigate
their disease (Lopez et al., 2011). Likewise selective deﬁciency of Npc1
in Purkinje neurons of the cerebellum results in selective Purkinje
cell loss while surrounded by wild-type glial cells (Ko et al., 2005).
Nevertheless, there is in vitro and in vivo evidence to suggest thatthe immune response does modify disease progression and pathol-
ogy. Firstly, when wild-type neurons were cultured with Npc1−/−
astrocytes, Npc1 deﬁciency in astrocytes resulted in decreased
neurite growth in wild-type neurons (Chen et al., 2007). Npc1−/−
astrocytes were demonstrated to release less estradiol and impor-
tantly, giving additional estradiol to neonatal Npc1−/− mice im-
proved their clinical outcome, suggesting a pathogenic role of
this estradiol deﬁciency. Secondly, reducing the immune response
in Npc1−/− mice with anti-inﬂammatory drugs was able to signif-
icantly prolong the life span of diseased mice (Smith et al., 2009).
Although it is likely that glial activation occurs secondary to an, as
yet unidentiﬁed, primary neuron-speciﬁc insult in Npc1−/− mice,
Fig. 4. Cortical astrocytosis and atrophy in Npc1−/−mice. a Immunohistochemical staining for glial ﬁbrillary acidic protein (GFAP) reveals astrocytosis in the somatosensory barrelﬁeld
cortex (S1BF), the primary visual cortex (V1) and the primarymotor cortex (M1) inNpc1−/−mice. Adjacent Nissl stained sections illustrate cortical laminar boundaries. Astrocytosis was
already evident in all cortical subﬁelds in 3 week old Npc1−/−mice and increased in intensity with disease progression, with the greatest density of astrocytes in sensory regions (V1 and
S1BF) compared tomotor (M1). Bands of particularly dense astrocytosis became evident in lamina VI of the S1BF in 9 week-old Npc1−/−mice (Scale bar; 200 μm). bMeasurement of the
thickness of cortical subﬁelds revealed selective atrophy of sensory cortical regions S1BF, V1 and primary auditory cortex (Au1) in 9 week-old Npc1−/−mice, but relative sparing of M1
and the lateral entorhinal cortex (LEnt). (Error bars show SEM, n=4–5, **, pb0.01, ***, pb0.001).
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and our study provides a robust basis to understand the staging
of these events.
Our data reveal that neuron loss in sensory thalamic nuclei is asso-
ciated with the most intense immunoreactivity for astrocyte and
microglial markers (Figs. 2, 3), however the relationship between
these events is complex. For example at 3 weeks of age the VPM
shows more intense microglial activation and astrocytosis comparedto the adjacent VPL (Figs. 2, 3). Surprisingly, the onset of neuron
loss was reversed in sequence in these two nuclei with reduced neu-
ron number already evident in the VPL at 3 weeks of age, and subse-
quently becoming signiﬁcant in the VPM at 6 weeks of age (Fig. 6).
However, in the cortex, although a low level of glial activation preced-
ed neuron loss, more intense reactive gliosis (in lamina VI of the
S1BF) only became evident after the onset of neuron loss in this re-
gion of Npc1−/−mice (Fig. 6). Our examination of the precise staging
Fig. 5.Microglial activation in the cortex ofNpc1−/−mice. a, b Immunohistochemical staining for the F4/80 (a) and CD68 (b) demonstrate earlymicroglial activation in the somatosensory
barrelﬁeld cortex (S1BF) of Npc1−/− mice. Reactive microglia were evenly distributed throughout all laminae, displaying very little laminar speciﬁcity (adjacent Nissl stained sections
illustrate cortical laminar boundaries). At the end stage of disease progression, a band of particularly dense microglia became evident in the dorsal part of lamina VI of the S1BF (a,
b). c F4/80 and CD68 immunoreactivity reveal distinctive rod-like morphology of microglia in the cortex of Npc1−/− mice. (Scale bar=200 μm in low power cortical views in a and
b, 20 μm in high power inserts and c).
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varies between brain regions in Npc1−/− mice, suggesting that the
cues causing glial reactivity may differ between brain regions.
By examining pathological events at different stages of disease,
our data reveal that pathological insults appear to be particularly pro-
nounced within interconnecting pathways. For example the early and
pronounced pathology in the VPM/VPL was followed by localised
gliosis in lamina VI of the S1BF, where neurons provide feedback
input to the thalamus. This may simply reﬂect the intrinsic vulnera-
bility of these particular neuron populations, but also raises the possi-
bility that these neuropathological changes have a trans-synapticcomponent. This might involve the loss of trophic inﬂuences upon af-
ferent neurons that are already compromised by Npc1 deﬁciency and
the recent development of mice in which Npc1 expression can be
inducibly expressed in speciﬁc neuron populations (Lopez et al.,
2011) will be a valuable to address such issues.
How this pathology of sensory thalamic pathways impacts upon
the disease phenotype is unclear. In human NPC disease, imaging
studies have found that the thalamus amongst other structures has
an altered signal compared to controls (Huang et al., 2011;
Walterfang et al., 2010). Interestingly, there is evidence for selective
pathology at multiple steps of sensory pathways in Npc1−/− mice,
Fig. 6. Sequential neuron loss in the thalamocortical system of Npc1−/− mice. a–c Optical fractionator estimates of neuron number in individual thalamic relay nuclei show signif-
icantly fewer neurons in the dorsal lateral geniculate nucleus (LGNd) and the ventral posterior medial nucleus (VPM) of Npc1−/− mice from 3 weeks of age, compared to control
mice and from 6 weeks of age in the ventral posterior lateral nucleus (VPL). d, e In the cortex of Npc1−/−mice, optical fractionator estimates of neuron number reveal progressive
loss of neurons in lamina VI of the S1BF, becoming signiﬁcant at 6 weeks of age (e) compared to relatively delayed onset of neuron loss in lamina IV, which only became signiﬁcant
at 9 weeks of age (d). f Diagram illustrating the interconnected pathways between a thalamic relay nucleus and the cortex. Crosses indicate the order of neuron loss observed in the
somatosensory relay system in Npc1−/− mice. (Error bars show SEM; n=4–5; * pb0.05; ** pb0.01; *** pb0.001 using one way ANOVA).
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(Ohara et al., 2004) and brain stem nuclei (Luan et al., 2008). Our
data shows that the somatosensory thalamocortical pathway (VPM/
VPL connecting to S1BF) displayed the most pronounced pathology,
with the interconnected Po nucleus that also relays somatosensory
input similarly displaying localised reactive gliosis (Table 1). The so-
matosensory system processes proprioceptive, nociceptive and tactile
information and in rodents the S1BF is involved with processing sen-
sory input from the whiskers (O'Leary et al., 1994). Although sensory
abnormalities are not commonly reported in NPC disease, if such de-
fects do occur, they are likely to go unrecognised or be masked by se-
vere neurological deterioration. Considering the early and profound
effects upon somatosensory pathways in Npc1−/− mice, it would be
informative to examine whether subtle pain or somatosensory abnor-
malities, are also evident in these mice.
Localised rod microglia, a distinct immune reaction?
In addition, our data also reveal new information about the nature
of this immune response in Npc1−/−mice. Our use of F4/80 and CD68
immunohistochemistry revealed microglia with an abnormal mor-
phology in the striatum and cortex of Npc1−/− mice, with long,
straight rod-like processes forming into clumps (Figs. 5, 7). Rod
microglia are reported to occur in models of ischaemic stroke (Ng
and Ling, 2001; Zhang et al., 1997) and extend processes along degen-
erating ﬁbre tracts (Schroeter et al., 2002) or along blood vessels (Lin
et al., 1998). The rod microglia observed in Npc1−/− mice were verylarge, extending beyond the size of multiple amoeboid microglia
and therefore appear much larger than those reported in stroke
(Schroeter et al., 2002; Zhang et al., 1997). This novel observation
raises the possibility that these microglia are surrounding degenerat-
ing axons (Baudry et al., 2003; Ong et al., 2001) and raises the ques-
tion of why they are apparent in such a localised fashion in the
ventral lateral striatum.
Reactive glia in the basal ganglia of Npc1−/− mice
In addition to the rod-like microglia in the striatum, we also found
localised activation of glia within other structures of the basal ganglia
of Npc1−/− mice including the globus pallidus and the substantia
nigra (Fig. 7). Astrocytosis and microglial activation have previously
been reported in these brain regions (Baudry et al., 2003; Luan
et al., 2008) and this was demonstrated to be associated with neuron
loss in the substantia nigra (Baudry et al., 2003; Luan et al., 2008; Ong
et al., 2001). The basal ganglia are associated with the modulation of
motor control (DeLong and Wichmann, 2009; Mink, 1996) and signs
of basal ganglia dysfunction, including dystonia are a common clinical
feature of NPC (Imrie et al., 2007). This localised basal ganglia pathol-
ogy is likely to be associated with broader pathology within these
interconnected motor pathways, with the cerebellum known to be
severely affected in NPC (Higashi et al., 1993; Sarna et al., 2003) and
localised reactive gliosis within thalamic nuclei relaying motor infor-
mation (Ventral lateral nucleus; Table 1). Interestingly, our data have
revealed that the dorsal part of the substantia nigra showed the
Fig. 7. Localised glial activation in the substantia nigra and striatum of Npc1−/−mice. a GFAP immunoreactivity reveals an increased astrocytosis in the substantia nigra of Npc1−/−
mice from 6 weeks of age, with predominance for the dorsal part of the substantia nigra pars reticularis (SNr). F4/80 and CD68 immunoreactivity reveal that microglial activation
precedes astrocytosis with microglia already activated from 3 weeks of age in the SNr. This microglial activation is progressive with an increased CD68 immunoreactivity in the
dorsal part of the substantia nigra from 6 weeks, but with microglia not fully transformed into amoeboid microglia until 9 weeks of age (high power pictures). b F4/80 and
CD68 immunoreactivity revealed microglia in the dorsal lateral part of the striatum to have an unusual rod-like morphology, which was already evident in 3 week old mice.
(Scale bar in a=200 μm and 10 μm in inserts; in b=20 μm).
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the most marked microglial activation in the striatumwas localised to
the ventral lateral part (Fig. 7). As well as being associated with motor
functions, the basal ganglia have more recently been demonstrated to
be involved in behaviours such as motivation, emotional drive, plan-
ning and cognition (Graybiel, 2005; Haber and Calzavara, 2009). Our
data suggest that pathological processes impact upon highly localised
pathways within the basal ganglia. Dysfunction of these speciﬁc path-
ways could potentially contribute to cognitive and behavioural symp-
toms, in addition to the motor symptoms evident in NPC disease
(Garver et al., 2007; Imrie et al., 2007).Synaptic abnormalities occur early in disease progression
While our counts of neuron numbers have provided a sensitive
measure of neuron loss (Fig. 6), degeneration of the neuron soma is
the terminal step in the neuropathological cascade. In Npc1−/− mice
silver staining reveals degenerating neuron terminals (Ong et al.,
2001), and demyelination has been reported early in disease progres-
sion (German et al., 2001; Takikita et al., 2004; Weintraub et al.,
1987) suggesting that the degenerative process may originate in the
distal parts of the neuron. Consistent with these data, our study
revealed atrophy of white matter structures early in disease
Fig. 8. Reactive gliosis and atrophy of white matter in Npc1−/− mice. a Localised intense GFAP and F4/80 immunoreactivity were evident in the corpus callosum of Npc1−/− mice.
GFAP immunoreactivity revealed a high level of astrocytosis was already evident at 3 weeks of age and F4/80 immunoreactivity revealed microglia to have transformed into amoeboid
morphology at this early age (inserts). b Likewise, very intense F4/80 immunoreactivity was evident in the internal capsule ofNpc1−/−mice from 3 weeks of age. c–d Cavalieri estimates
reveal reduced volume of the corpus callosum and internal capsule throughout the life span of Npc1−/−mice compared to age matched controls. (Scale bar in b=50 μm and 20 μm in
inserts; in c=100 μm; Error bars show SEM; n=4–5, * pb0.05; ** pb0.01; *** pb0.001 using one way ANOVA).
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microglial activation in the white matter, with microglia already
fully transformed into amoeboid microglia by 3 weeks of age
(Fig. 8a). Likewise in the human disease, a widespread white matter
atrophy has been found in patients (Walterfang et al., 2010).
With regard to the synapse, the NPC1 protein is present in termi-
nal axons and synapses (Karten et al., 2006; Patel et al., 1999; Xu et
al., 2010) and presynaptic terminals are enlarged and show signs of
degeneration (Ohara et al., 2004). Importantly, these changes appear
to be functionally relevant, with Npc1 deﬁcient synapses showing in-
creased spontaneous activity (Wasser et al., 2007) and delayed exo-
cytosis (Xu et al., 2010). Cholesterol is important in the correct
functioning of synapses and cholesterol depletion in nerve terminals
due to the defect in cholesterol trafﬁcking in Npc1−/− brain is thought
to be responsible for this synaptic dysfunction (Wasser et al., 2007).
Our survey of pre- and post-synaptic proteins has demonstrated a
marked redistribution of presynaptic proteins that occurs early in dis-
ease progression in Npc1−/−mice (Fig. 9). Our novel data details that
distinct synaptic phenotypes are evident within different regions of
the CNS; presynaptic protein redistribution was profound early in dis-
ease in subcortical grey and white matter structures (Fig. 9), whereasthe cortex remained relatively spared, even at disease end stage. The
challenge will now lie in determining if there is a mechanistic link be-
tween these events and the subsequent loss of neurons in these
pathways.
Our data imply that in Npc1−/− mice, a proportion of presynaptic
markers may fail to reach the nerve terminals because they become
aggregated within axonal spheroids in the white matter (Fig. 9c).
The occurrence of axonal spheroids correlates with neurological
symptoms and severity in LSD models, and therefore axonal spheroid
formation is thought to contribute to neuronal dysfunction (Walkley
et al., 1991). Our observation that presynaptic markers are aggregated
within axonal spheroids suggests that axonal transport of these pro-
teins is disturbed in both Npc1−/− mice. Disrupted axonal transport
has already been reported in Npc1−/− mice (Neufeld et al., 1999;
Zhang et al., 2001) and our data imply that this also results in a propor-
tion of presynaptic proteins failing to reach their synaptic target. Fur-
thermore a loss of presynaptic input onto neuronal soma in the
thalamus may have a secondary contribution to neuron loss. Despite
the marked presynaptic phenotype in Npc1−/− mice, we found little
evidence for postsynaptic rearrangements. This is consistent with Xu
et al. (2010) who reported no difference in the expression of
Fig. 9. Altered distribution of presynaptic markers in Npc1−/− mice. a Immunohistochemical staining for synaptophysin (Syp) at the end stage of disease revealed aggregates of
immunoreactivity, most prominently in the internal capsule (X), reticular (+) and ventral posterior (*) nucleus of the thalamus in Npc1−/− mice. b Higher power pictures from
the ventral posterior nucleus (VPM/VPL) and internal capsule demonstrate these large aggregates to be immunoreactive for three presynaptic markers; synaptophysin, VAMP2
and SNAP25. c Dual channel immunoﬂuorescence staining for the presynaptic marker synaptophysin and the GABAergic marker GAD65/67 reveal partial co-localisation of synaptic
aggregateswith GABAergic axonal spheroids in the VPM (ventral medial posterior nucleus of the thalamus) ofNpc1−/−mice. Yellow arrows indicate aggregates immunoreactive for both
the synaptic marker and GAD65/67, red arrows indicate aggregates only immunoreactive for synaptophysin/VAMP2 and green arrows indicate aggregates only immunoreactive for
GAD65/67. (Scale bar in a=200 μm; in b and c=10 μm).
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ceptors in Npc1−/− neurons. Their data and ours suggest that the dis-
ease process impacts the synapse in an asymmetrical fashion.Fig. 10. No change in the level of expression of synaptic markers. Western blots on
enriched synaptic fractions from cortical and subcortical forebrain indicate no change
in the level of expression of synaptic markers. Actin was used as a loading control.
Syp; Synaptophysin.These observations of axonal and synaptic abnormalities in the
thalamocortical system of Npc1−/− mice again highlight that a series
of pathological events occur within these interconnected pathways.
Although we have systematically mapped the order of events through
these pathways, key questions remain about the apparent vulnerabil-
ity of these neurons and how it relates to the catabolic defect in this
disorder. For example, why do these particular neurons succumb to
the disease process, while others remain unaffected, despite the
same genetic deﬁciency being present in all cells? The simplest expla-
nation could be that the burden of storage material could gradually
increase over time until a certain threshold is reached by which indi-
vidual neurons and pathways succumb to the disease. However, with
the precise function of NPC1 remaining elusive, it remains unclear
whether the primary pathology is a direct result of storage material
accumulation or another as yet unidentiﬁed consequence of Npc1 de-
ﬁciency. Our data provide a new perspective, revealing a number of
1099S.N.R. Pressey et al. / Neurobiology of Disease 45 (2012) 1086–1100events that occur prior to and alongside neuron loss and highlighting
that these occur in a pathway dependent manner.
Conclusion
In conclusion, this study has revealed a series of novel neuropath-
ological alterations in the CNS of Npc1−/−mice that were particularly
pronounced within the sensory thalamocortical system. Our data add
signiﬁcantly to the current literature by demonstrating an early acti-
vation of astrocytes and microglia in Npc1−/− mice, implicating the
thalamus and basal ganglia as speciﬁc foci of disease pathology.
These ﬁndings suggest that there are multiple components of this im-
mune response, with an early low level glial activation followed by
the sequential appearance of localised patches of intense glial reactiv-
ity becoming evident with subsequent disease progression. We dem-
onstrate that these regions, which display particularly pronounced
reactive gliosis also display rearrangement of presynaptic markers,
suggesting a pathological impact upon distal parts of the neuron. Ex-
amination of the onset and progression of events through the disease
course suggests that pathology progresses through the intercon-
nected nuclei of the thalamocortical system. Why these intercon-
nected pathways are vulnerable to disease remains unclear. Further
understanding of the impact of loss of Npc1 upon the brain will help
to elucidate the degenerative process in NPC and is necessary to un-
derstand and why loss of this gene has such severe neurodegenera-
tive consequences.
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